patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_375469 | REC_0011701 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.1 | 60 | male | 1 | 12 | 5.1 | 5 | osimertinib 80 mg daily | 11.7 | true | MSI-H | 2026-03-15T05:35:59.791443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581408 | REC_0011702 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 10.2 | 85 | female | 2 | 8 | 7.3 | 6 | osimertinib 80 mg daily | 9.1 | true | MSI-H | 2026-03-15T05:35:59.791683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210363 | REC_0011703 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 13.2 | 62 | male | 1 | 10 | 7.7 | 2 | osimertinib 80 mg daily | 21.8 | true | MSS | 2026-03-15T05:35:59.791920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_261059 | REC_0011704 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 6.1 | 72 | female | 1 | 17 | 6.5 | 7 | osimertinib 80 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:59.792208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464068 | REC_0011705 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 9.4 | 73 | female | 1 | 22 | 6.7 | 2 | sotorasib 960 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:59.792449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_497150 | REC_0011706 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 3.2 | 75 | female | 2 | 38 | 5.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.3 | true | MSS | 2026-03-15T05:35:59.792679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708610 | REC_0011707 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.8 | 67 | female | 1 | 66 | 6.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:35:59.792913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647724 | REC_0011708 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 14.8 | 50 | male | 0 | 13 | 5.4 | 9 | alectinib 600 mg BID | 11.8 | true | MSI-H | 2026-03-15T05:35:59.793150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216397 | REC_0011709 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 13.4 | 72 | female | 2 | 18 | 6.7 | 6 | entrectinib 600 mg daily | 14.2 | false | MSS | 2026-03-15T05:35:59.793382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770311 | REC_0011710 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12 | 63 | male | 1 | 6 | 7.8 | 1 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:59.793617+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312960 | REC_0011711 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 8.6 | 83 | male | 2 | 4 | 5.5 | 2 | sotorasib 960 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:59.793849+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725419 | REC_0011712 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 15.1 | 56 | male | 1 | 17 | 7.4 | 4 | sotorasib 960 mg daily | 11.6 | true | MSI-H | 2026-03-15T05:35:59.794084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233594 | REC_0011713 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 19 | 6.6 | 69 | female | 1 | 74 | 5 | 0 | carboplatin + paclitaxel + pembrolizumab | 18.3 | false | MSS | 2026-03-15T05:35:59.794311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617485 | REC_0011714 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.6 | 72 | male | 2 | 42 | 5.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.5 | true | MSS | 2026-03-15T05:35:59.794606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634610 | REC_0011715 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 4.9 | 63 | male | 1 | 2 | 5.2 | 2 | alectinib 600 mg BID | 13.2 | false | MSS | 2026-03-15T05:35:59.794844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614897 | REC_0011716 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12 | 74 | female | 2 | 20 | 7.3 | 1 | osimertinib 80 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:35:59.795082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639267 | REC_0011717 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 3.1 | 75 | female | 2 | 19 | 7.5 | 2 | pembrolizumab 200 mg q3w | 16 | false | MSS | 2026-03-15T05:35:59.795314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282303 | REC_0011718 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.3 | 60 | female | 1 | 16 | 6.6 | 4 | osimertinib 80 mg daily | 7.1 | false | MSI-H | 2026-03-15T05:35:59.795548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744984 | REC_0011719 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 7.5 | 67 | female | 0 | 20 | 5.3 | 6 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:59.795778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972058 | REC_0011720 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 4 | 65 | male | 0 | 21 | 4.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 28.9 | false | MSS | 2026-03-15T05:35:59.796009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700430 | REC_0011721 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 21 | 11.9 | 72 | female | 1 | 21 | 6.1 | 0 | osimertinib 80 mg daily | 31.9 | true | MSI-H | 2026-03-15T05:35:59.796271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212648 | REC_0011722 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.8 | 71 | female | 1 | 17 | 4 | 6 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:35:59.796504+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694525 | REC_0011723 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.2 | 54 | female | 0 | 47 | 6.8 | 7 | pembrolizumab 200 mg q3w | 12.7 | false | MSS | 2026-03-15T05:35:59.796735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502879 | REC_0011724 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 13.8 | 73 | male | 2 | 10 | 5.7 | 2 | osimertinib 80 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:35:59.796969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191199 | REC_0011725 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 12.1 | 49 | male | 0 | 18 | 6.1 | 1 | entrectinib 600 mg daily | 16.7 | false | MSS | 2026-03-15T05:35:59.797204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281221 | REC_0011726 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 7.9 | 60 | male | 1 | 16 | 5.6 | 4 | pembrolizumab 200 mg q3w | 10.5 | false | MSS | 2026-03-15T05:35:59.797437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766133 | REC_0011727 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 19.6 | 69 | male | 0 | 28 | 4.8 | 6 | entrectinib 600 mg daily | 19.8 | false | MSS | 2026-03-15T05:35:59.797720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692592 | REC_0011728 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.3 | 54 | female | 0 | 17 | 3.5 | 4 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:59.797957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400464 | REC_0011729 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 15.1 | 54 | male | 0 | 25 | 5.2 | 5 | entrectinib 600 mg daily | 6.1 | false | MSI-H | 2026-03-15T05:35:59.798193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569946 | REC_0011730 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 15.9 | 70 | male | 2 | 21 | 5.5 | 5 | sotorasib 960 mg daily | 7.1 | false | MSS | 2026-03-15T05:35:59.798430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542625 | REC_0011731 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 13.5 | 66 | female | 0 | 15 | 5.6 | 2 | osimertinib 80 mg daily | 20.8 | true | MSI-H | 2026-03-15T05:35:59.798664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672581 | REC_0011732 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 12.1 | 49 | female | 0 | 11 | 5.5 | 2 | alectinib 600 mg BID | 15.8 | false | MSS | 2026-03-15T05:35:59.798899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747236 | REC_0011733 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 11.9 | 61 | male | 1 | 21 | 7 | 4 | entrectinib 600 mg daily | 17.1 | false | MSI-H | 2026-03-15T05:35:59.799137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480816 | REC_0011734 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 4.3 | 60 | male | 0 | 33 | 7.1 | 7 | pembrolizumab 200 mg q3w | 11.6 | true | MSS | 2026-03-15T05:35:59.799367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521101 | REC_0011735 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 6.6 | 59 | female | 1 | 72 | 5.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 8 | true | MSS | 2026-03-15T05:35:59.799599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951586 | REC_0011736 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13 | 68 | female | 1 | 12 | 5.3 | 7 | entrectinib 600 mg daily | 16.8 | true | MSS | 2026-03-15T05:35:59.799829+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804560 | REC_0011737 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 14 | 70 | female | 1 | 6 | 5.6 | 1 | alectinib 600 mg BID | 7 | false | MSI-H | 2026-03-15T05:35:59.800059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838442 | REC_0011738 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 12.1 | 63 | male | 0 | 7 | 5.7 | 8 | pembrolizumab 200 mg q3w | 8.3 | true | MSS | 2026-03-15T05:35:59.800428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147993 | REC_0011739 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5.3 | 77 | female | 2 | 11 | 5.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 26.9 | false | MSS | 2026-03-15T05:35:59.800659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786573 | REC_0011740 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 7 | 72 | female | 1 | 26 | 8.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.8 | true | MSS | 2026-03-15T05:35:59.800941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_749920 | REC_0011741 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11 | 73 | female | 2 | 15 | 5 | 4 | osimertinib 80 mg daily | 6.3 | false | MSS | 2026-03-15T05:35:59.801180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442521 | REC_0011742 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 7.2 | 75 | male | 3 | 6 | 5.7 | 2 | pembrolizumab 200 mg q3w | 17.3 | false | MSS | 2026-03-15T05:35:59.801412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543614 | REC_0011743 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 10.3 | 68 | female | 0 | 26 | 5.9 | 7 | alectinib 600 mg BID | 13.5 | true | MSS | 2026-03-15T05:35:59.801646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172755 | REC_0011744 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 7.7 | 70 | female | 2 | 28 | 6.6 | 6 | osimertinib 80 mg daily | 16.8 | false | MSS | 2026-03-15T05:35:59.801872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207108 | REC_0011745 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 8.5 | 73 | female | 2 | 13 | 3.8 | 0 | entrectinib 600 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:59.802104+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560965 | REC_0011746 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 10.8 | 81 | female | 2 | 10 | 6.8 | 2 | sotorasib 960 mg daily | 20.2 | true | MSI-H | 2026-03-15T05:35:59.802335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457859 | REC_0011747 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 10.2 | 68 | female | 0 | 21 | 7.7 | 1 | alectinib 600 mg BID | 22.8 | true | MSS | 2026-03-15T05:35:59.802568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258120 | REC_0011748 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 4.9 | 70 | female | 2 | 80 | 4.7 | 7 | pembrolizumab 200 mg q3w | 10 | true | MSS | 2026-03-15T05:35:59.802794+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363230 | REC_0011749 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.5 | 47 | male | 0 | 34 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 15 | true | MSS | 2026-03-15T05:35:59.803026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409324 | REC_0011750 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.4 | 64 | female | 0 | 33 | 7.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 9.8 | false | MSS | 2026-03-15T05:35:59.803257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801537 | REC_0011751 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 3.8 | 56 | female | 1 | 12 | 6 | 7 | pembrolizumab 200 mg q3w | 5.2 | true | MSS | 2026-03-15T05:35:59.803488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931409 | REC_0011752 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 13 | 60 | female | 1 | 9 | 4.7 | 6 | entrectinib 600 mg daily | 17.1 | true | MSI-H | 2026-03-15T05:35:59.803720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889384 | REC_0011753 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7 | 80 | female | 1 | 63 | 6.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.8 | false | MSS | 2026-03-15T05:35:59.803992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365525 | REC_0011754 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 16.4 | 77 | female | 2 | 17 | 5 | 2 | alectinib 600 mg BID | 29.9 | true | MSI-H | 2026-03-15T05:35:59.804258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856365 | REC_0011755 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 15.3 | 69 | female | 1 | 18 | 4.6 | 7 | entrectinib 600 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:35:59.804492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901628 | REC_0011756 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 9.2 | 75 | male | 2 | 86 | 6.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.5 | false | MSS | 2026-03-15T05:35:59.804726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536323 | REC_0011757 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.8 | 61 | male | 0 | 55 | 5.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.7 | false | MSS | 2026-03-15T05:35:59.804958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130567 | REC_0011758 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 11.9 | 70 | male | 2 | 9 | 6.6 | 1 | alectinib 600 mg BID | 4.3 | false | MSS | 2026-03-15T05:35:59.805193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210360 | REC_0011759 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 13.9 | 70 | female | 2 | 12 | 8.1 | 1 | alectinib 600 mg BID | 13.3 | false | MSS | 2026-03-15T05:35:59.805426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141555 | REC_0011760 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 11.6 | 62 | female | 0 | 12 | 7.8 | 4 | sotorasib 960 mg daily | 12.7 | false | MSI-H | 2026-03-15T05:35:59.805662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378403 | REC_0011761 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 13.7 | 68 | female | 0 | 21 | 3.5 | 1 | entrectinib 600 mg daily | 27.5 | false | MSI-H | 2026-03-15T05:35:59.805896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340632 | REC_0011762 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 12.8 | 58 | female | 1 | 9 | 6.8 | 4 | osimertinib 80 mg daily | 13 | true | MSI-H | 2026-03-15T05:35:59.806132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205315 | REC_0011763 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.3 | 65 | male | 1 | 18 | 4.9 | 4 | sotorasib 960 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:59.806364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319072 | REC_0011764 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.1 | 68 | male | 0 | 8 | 4.3 | 6 | sotorasib 960 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:59.806601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334834 | REC_0011765 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 24.9 | 79 | male | 1 | 18 | 5.7 | 6 | alectinib 600 mg BID | 11.7 | true | MSS | 2026-03-15T05:35:59.806837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944164 | REC_0011766 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.1 | 58 | female | 0 | 16 | 5.4 | 5 | sotorasib 960 mg daily | 7 | true | MSI-H | 2026-03-15T05:35:59.807127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684489 | REC_0011767 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 12.7 | 71 | female | 2 | 14 | 7 | 1 | alectinib 600 mg BID | 10.4 | false | MSS | 2026-03-15T05:35:59.807502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602581 | REC_0011768 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.8 | 57 | female | 1 | 62 | 5.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 17.2 | true | MSS | 2026-03-15T05:35:59.807766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535471 | REC_0011769 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 8.8 | 69 | female | 0 | 19 | 5.1 | 2 | alectinib 600 mg BID | 17 | false | MSS | 2026-03-15T05:35:59.808033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834823 | REC_0011770 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 15 | 3.6 | 62 | male | 1 | 17 | 7.3 | 8 | osimertinib 80 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:59.808322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714318 | REC_0011771 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 4.2 | 79 | female | 2 | 54 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.7 | false | MSS | 2026-03-15T05:35:59.808560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249483 | REC_0011772 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 15.3 | 79 | female | 2 | 14 | 6.7 | 1 | osimertinib 80 mg daily | 18.9 | false | MSI-H | 2026-03-15T05:35:59.808802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644011 | REC_0011773 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 7.7 | 69 | female | 1 | 10 | 4.4 | 1 | sotorasib 960 mg daily | 27.6 | true | MSS | 2026-03-15T05:35:59.809035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706854 | REC_0011774 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 4.7 | 82 | female | 0 | 17 | 4.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.7 | true | MSS | 2026-03-15T05:35:59.809280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482290 | REC_0011775 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 9.5 | 79 | female | 1 | 6 | 8 | 2 | sotorasib 960 mg daily | 22.7 | true | MSS | 2026-03-15T05:35:59.809527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805662 | REC_0011776 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 17 | 8.5 | 77 | female | 3 | 10 | 3.9 | 3 | pembrolizumab 200 mg q3w | 19 | true | MSS | 2026-03-15T05:35:59.809762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729897 | REC_0011777 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 14.2 | 70 | female | 3 | 12 | 2.6 | 0 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:59.810000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345797 | REC_0011778 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 10.5 | 76 | female | 1 | 5 | 4 | 4 | entrectinib 600 mg daily | 12.6 | true | MSI-H | 2026-03-15T05:35:59.810237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656209 | REC_0011779 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 15.4 | 70 | female | 2 | 15 | 5.3 | 7 | alectinib 600 mg BID | 8.8 | false | MSS | 2026-03-15T05:35:59.810581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831231 | REC_0011780 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.1 | 51 | female | 0 | 20 | 4.7 | 6 | alectinib 600 mg BID | 12.1 | true | MSI-H | 2026-03-15T05:35:59.810826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587567 | REC_0011781 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 10.2 | 66 | female | 0 | 19 | 7.4 | 7 | entrectinib 600 mg daily | 13.4 | true | MSS | 2026-03-15T05:35:59.811062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977661 | REC_0011782 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 12.8 | 65 | female | 0 | 7 | 5.6 | 1 | alectinib 600 mg BID | 15.8 | false | MSS | 2026-03-15T05:35:59.811298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276823 | REC_0011783 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 19 | 12.1 | 63 | female | 1 | 11 | 5.4 | 0 | sotorasib 960 mg daily | 45.5 | false | MSS | 2026-03-15T05:35:59.811536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192324 | REC_0011784 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 8.3 | 83 | male | 1 | 15 | 4.4 | 2 | pembrolizumab 200 mg q3w | 13.6 | true | MSS | 2026-03-15T05:35:59.811767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398198 | REC_0011785 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 14.2 | 68 | male | 1 | 15 | 5.5 | 8 | osimertinib 80 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:59.812003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684628 | REC_0011786 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 8.7 | 74 | female | 1 | 16 | 4.5 | 2 | alectinib 600 mg BID | 17.3 | true | MSS | 2026-03-15T05:35:59.812300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245933 | REC_0011787 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 3.3 | 61 | female | 1 | 11 | 6.4 | 1 | entrectinib 600 mg daily | 11.6 | true | MSS | 2026-03-15T05:35:59.812548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345942 | REC_0011788 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.8 | 60 | male | 1 | 47 | 7.4 | 3 | carboplatin + paclitaxel + pembrolizumab | 11 | true | MSS | 2026-03-15T05:35:59.812783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344262 | REC_0011789 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.3 | 70 | female | 2 | 12 | 5.7 | 4 | osimertinib 80 mg daily | 5 | true | MSI-H | 2026-03-15T05:35:59.813020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436878 | REC_0011790 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 8.4 | 47 | male | 0 | 17 | 7.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.2 | true | MSS | 2026-03-15T05:35:59.813250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415829 | REC_0011791 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 6.7 | 63 | female | 0 | 26 | 5.8 | 7 | pembrolizumab 200 mg q3w | 12 | true | MSS | 2026-03-15T05:35:59.813481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157084 | REC_0011792 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 8.3 | 59 | female | 0 | 21 | 4.6 | 5 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:59.813775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711824 | REC_0011793 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 20 | 10.6 | 86 | female | 1 | 13 | 5.2 | 0 | entrectinib 600 mg daily | 44.5 | false | MSS | 2026-03-15T05:35:59.814011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214275 | REC_0011794 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 18 | 56 | male | 1 | 11 | 5.2 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.814248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602943 | REC_0011795 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 8.8 | 62 | female | 0 | 12 | 5.7 | 3 | osimertinib 80 mg daily | 15.4 | false | MSS | 2026-03-15T05:35:59.814480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310108 | REC_0011796 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 16 | 14.6 | 76 | female | 1 | 5 | 6.8 | 1 | sotorasib 960 mg daily | 22.2 | true | MSI-H | 2026-03-15T05:35:59.814711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283960 | REC_0011797 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 15 | 8 | 60 | female | 1 | 6 | 6.2 | 0 | entrectinib 600 mg daily | 37.3 | true | MSS | 2026-03-15T05:35:59.814943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714912 | REC_0011798 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 6.1 | 60 | female | 0 | 64 | 6.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 13 | false | MSS | 2026-03-15T05:35:59.815178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743594 | REC_0011799 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 33 | 7.8 | 61 | male | 1 | 45 | 5.6 | 2 | pembrolizumab 200 mg q3w | 24 | false | MSS | 2026-03-15T05:35:59.815414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753080 | REC_0011800 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 15.9 | 72 | male | 3 | 4 | 3.8 | 4 | pembrolizumab 200 mg q3w | 14.3 | false | MSI-H | 2026-03-15T05:35:59.815649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.